Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

by | Apr 11, 2025 | Clinical Trials | 0 comments

​ Conditions: Advanced NSCLC

Interventions: Drug: JS207 injection

Sponsors: Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting Conditions: Advanced NSCLC
Interventions: Drug: JS207 injection
Sponsors: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *